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.2013.04Abstract Background: Treatment of anemia in children with predialysis chronic kidney disease
(CKD) has been facilitated by the administration of recombinant human erythropoietin (rHuEpo).
The aim of this study was to evaluate the effect of rHuEpo on the correction of anemia and to study
its effect on the progression of CKD in predialysis patients.
Methods: This study was done at the New Children’s Hospital, Cairo University, included 40
patients with CKD and renal anemia on conservative management. The patients were divided into
two groups; group I (received rHuEpo) and group II (did not receive rHuEpo). For all patients,
clinical assessment and routine laboratory investigation were recorded every 2 weeks, in addition
to iron indices and ultrasonography. Glomerular ﬁltration rate (GFR) was calculated every 2 weeks
and the rate of decline of GFR (DGFR) was determined over 6 months preceding starting follow
up. GFR was also determined over a follow up period of 12 months.
Results: There was a statistically signiﬁcant difference between the initial and ﬁnal levels of hemo-
globin (Hb) and hematocrit (Hct) in group I. Also, there was a statistically signiﬁcant difference
between the two groups as regards Hb and Hct levels at the end of the study. The progression of
CKD is already slower before T0 (the time of starting rHuEpo administration) in group I and also
decreased after T0, with highly statistically signiﬁcant difference.
Conclusion: The study concluded that rHuEpo therapy is beneﬁcial for correction of renal anemia
and its early treatment is a useful intervention for slowing the progression in patients with CKD.
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.008Introduction
Chronic anemia is a common feature of advanced chronic kid-
ney disease (CKD). It frequently develops in chronic renal fail-
ure (CRF) when the glomerular ﬁltration rate (GFR) falls
below 20–30 ml/min.1
As kidney function declines, the likelihood of anemia asso-
ciated with erythropoietin deﬁciency increases because thehe Egyptian Pediatric Association.
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Figure 1 The etiology of chronic kidney disease (CKD) in the
studied patients.
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erythropoietin.2 Successful treatment of renal anemia with re-
combinant human erythropoietin (rHuEpo) conﬁrms inade-
quate erythropoietin production as the main cause.3
Among the therapeutic interventions that could possibly
slow the progression of CKD is the correction of anemia
through the administration of rHuEpo.4 Partial correction of
anemia with rHuEpo has been shown to markedly improve
the general condition and quality of life of predialysis patients,
but the effects of rHuEpo therapy on blood pressure and the
rate of progression of CRF are still disputed.3
Intravenous iron has been shown to improve responsive-
ness to rHuEpo in selected patients with CKD patients.5 In
the absence of iron replacement, development of iron deﬁ-
ciency during rHuEpo therapy is common and deﬁcient avail-
able iron is the most common cause of initial poor response to
erythropoietin.6
Subjects and methods
This study was done from December 2007 to May 2009 at the
nephrology clinic, New Children’s Hospital, Cairo University.
The study included 40 randomly selected patients, 1–15 years
old, with CKD on conservative management. All patients have
anemia with hematocrit (Hct) level from 30% to 36%. This
study was approved by the ethical scientiﬁc committee in the
Cairo University hospital and was conducted in accordance
with the University bylaws for human research. All caretakers
have given their informed consent. Cases of acute renal failure
or hematological disease other than anemia were excluded
from the study.
The patientswere randomly divided into two groups (The pa-
tients’ ﬁles numbers are arranged serially, ﬁles were randomly
selected electronically using Microsoft ofﬁce Excel 2007):
Group I (received rHuEpo subcutaneously {SC} once
weekly) and group II (did not received rHuEpo), each com-
posed of 20 patients. In both groups the GFR was calculated
every 2 weeks and the rate of decline of GFR (DGFR) was
determined over 6 months preceding the start of follow up,
which was the time of starting rHuEpo administration in
group I and was mentioned as T0. GFR was also determined
over the follow up period.
For all patients, clinical assessment and investigation were
recorded
Clinical data included: age, gender, etiology of nephropathy,
measurement of blood pressure, weight, height, dose of rHu-
Epo and use of antihypertensive treatment and were recorded
every 2 weeks.
Investigation: blood urea nitrogen (BUN), serum creatinine,
serum calcium, phosphate, alkaline phosphatase, albumin,
complete blood picture (CBC), serum iron, ferritin, total iron
binding capacity (TIBC), transferrin saturation (TSAT) and
arterial blood gases (ABG) and also abdomino-pelvic ultraso-
nography were done for all patients.
Statistical analysis
All patient information was tabulated and processed using
SPSS 14.0. For quantitative variables, means and medians(as a measure of central tendency), standard deviation, range
and minimum and maximum (as measures of variability) were
used. Frequency and percentage are presented for qualitative
variables. Chi-square test and Fisher’s exact test were used
to estimate differences in qualitative variables.
Results
Our study included 40 patients, following up at the nephrology
clinic, with CKD on conservative management, with anemia
(Hct level from 30% to 36%). The patients were divided into
two groups; group I (received rHuEpo SC once weekly) and
group II (did not received rHuEpo), each composed of 20 pa-
tients. Their age ranged from 2 to 14 years (mean ± SD=
8.93 ± 3.67). The etiologies of CKD are shown in Fig. 1.
There was no statistically signiﬁcant difference with respect
to the distribution of original renal disease between the two
groups. Table 1 shows sex distribution, weight and height of
the studied groups.
Ten patients (25%) (seven patients in group I and three pa-
tients in group II) were hypertensive, with systolic or diastolic
blood pressure greater than the 95th percentile. The propor-
tion of patients receiving angiotensin-converting enzyme
(ACE) inhibitors was similar in both groups. Table 2 shows
the duration of conservative treatment, blood pressure of the
studied patients at the start (T0) and at the end of the study
and laboratory investigations in the two studied groups.
By ultrasound examination, the size of the kidneys was small
in 28 patients (70%) and small and atrophic in nine patients
(22.5%). Twenty patients (50%) had back pressure changes
and three patients (7.5%) had renal stones. There was no statis-
tically signiﬁcant difference between the two groups.
Fig. 2 shows types of anemia in all studied patients. Micro-
cytic hypochromic anemia was prevalent in group I while func-
tional iron deﬁciency was prevalent in group II, with
statistically signiﬁcant difference between the two groups.
All patients received iron supplement; 12 (30%) patients re-
ceived IV iron (four in group I and eight in group II) and 28
(70%) received oral iron (16 in group I and 12 in group II) with
no statistically signiﬁcant difference between the two groups.
There was statistically signiﬁcant difference between the
two groups as regards transferrin saturation (TSAT) which
Table 1 Sex distribution, height and weight in the studied
groups.
Group I (N= 20) Group II (N= 20)
Sex
Male 9 11
Female 11 9
Height below 5th percentile 11 14
Height above 5th percentile 9 6
Weight below 5th percentile 8 15
Weight above 5th percentile 12 5
Table 2 Duration of conservative treatment, blood pressure
and laboratory investigations in the studied groups.
Group I Group II p-Value
Duration of conservative
treatment (years)
3.47 ± 2.05 3.15 ± 1.4 >0.05
SBP at T0 (mmHg) 88.5 ± 8.7 90.5 ± 11.5 >0.05
DBP at T0 (mmHg) 56.5 ± 4.8 59 ± 7.5 >0.05
SBP at end (mmHg) 91 ± 18 92.5 ± 10.1 >0.05
DBP at end (mmHg) 60.5 ± 11.9 59 ± 4.4 >0.05
Na (meq/L) 138.65 ± 3.28 140.50 ± 4.44 >0.05
K (meq/L) 4.71 ± 0.84 4.47 ± 0.75 >0.05
PH 7.31 ± 0.05 7.29 ± 0.057 >0.05
HCO3 (meq/L) 19.78 ± 3.02 17.57 ± 2.71 >0.05
Albumin (mg/dl) 3.70 ± 0.46 3.68 ± 0.47 >0.05
Total calcium (mg/dl) 9.01 ± 1.3 8.92 ± 0.87 >0.05
Phosphorous (mg/dl) 4.66 ± 1.01 5.48 ± 1.42 >0.05
ALP (mg/dl) 419.10 ± 357.57 475.70 ± 315 >0.05
BUN (mg/dl) 37.70 ± 13.53 43.45 ± 11.33 >0.05
Creatinine (mg/dl) 2.17 ± 0.75 2.70 ± 1.16 >0.05
GFR (ml/min/1.73m2) 33.2 ± 12.6 34.1 ± 15.3 >0.05
p< 0.05 is signiﬁcant, p> 0.05 is not signiﬁcant.
SBP, systolic blood pressure; DBP, diastolic blood pressure; T0, the
start of rHuEpo administration in group I; Na, sodium; K,
potassium; HCO3, bicarbonate; ALP, alkaline phosphatase; BUN,
blood urea nitrogen; GFR, and glomerular ﬁltration rate.
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Figure 2 Types of anemia in the two groups of the studied
patients.
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Figure 3 Hb of groups I and II at start of follow up and at the
end of the study.
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(33.87 ± 6.21).
In group I, there was statistically signiﬁcant difference be-
tween the initial and ﬁnal hemoglobin (Hb) and Hct levels,
as shown in Figs. 3 and 4.
Also, there was a highly statistically signiﬁcant difference
between the two groups as regards Hb and Hct levels at the
end of the study, with p-value <0.001, as shown in Table 3.
The rate of decline of the glomerular ﬁltration rate (DGFR)
did not change in group II; with a mean DGFR value of
0.55 ± 0.48 before versus 0.57 ± 0.44 after T0 (difference is
not signiﬁcant). In contrast, the progression of CRF is already
slower before T0 in group I with a mean DGFR value of
0.36 ± 0.16 and decreased to 0.26 ± 0.15 after T0, with highly
statistically signiﬁcant difference as shown in Table 4.
The slope of DGFR change in rHuEpo-treated group was
reduced by more than 50% in 10 patients (decreased from
0.39 ± 0.06 to 0.18 ± 0.03) whereas DGFR did not signiﬁ-
cantly change in the other 10 rHuEpo-treated patients. Simi-
larly, the initial and ﬁnal value of GFR did not signiﬁcantly
differ between the two groups. When comparing the 10 pa-
tients whose progression was slowed with the other 10 patients,
the only difference is the distribution of original renal disease
between the two subgroups; ﬁve of the patients with slowed
progression had obstructive uropathy (difference is statistically
signiﬁcant), whereas chronic glumerulonephritis and inherited
renal disease were present in seven of the 10 patients with un-
changed progression.
Discussion
Chronic kidney disease (CKD) patients with anemia need
higher health care costs compared with patients without ane-
mia and compared with other diseases known to have a high
prevalence of associated anemia (such as cancer).7
Concerning the etiology of CRF in our studied patients, 15
out of 40 patients (37.5%) had obstructive uropathy, another
15 (37.5%) had unknown etiology, seven patients (17.5%)
had chronic glureulonephritis and three patients (7.5%) had
inherited diseases (two oxalosis and cystinosis in one).
Collins et al. (2003),8 reported that the unknown nephrop-
athy was 17.95% and Seikaly et al.(2003),9 reported it as
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Figure 4 Hct of groups I and II at start of follow up and at the
end of the study.
Table 3 Hb and Hct of group I and group II at the end of the
study.
Group I Group II p-Value
Hb at the end (g/dl) 11.13 ± 1.4 9.5 ± 0.92 <0.001*
Hct at the end (%) 33.24 ± 4.0 28.56 ± 2.41 <0.001*
Hb, hemoglobin; Hct, hematocrit.
* p< 0.05 is signiﬁcant, p> 0.05 is not signiﬁcant.
Table 4 Variation of the rate of decline of GFR (DGFR) in
the studied patients.
DGFR before
T0 (ml/min/1.73m2/
month)
DGFR after
T0 (ml/min/
1.73m2/month)
p-Value
Group I 0.36 ± 0.16 0.26 ± 0.15 <0.001*
Group II 0.55 ± 0.48 0.57 ± 0.44 >0.05
T0, the start of rHuEpo administration in group I; GFR, glomer-
ular ﬁltration rate; DGFR, variation of the rate of decline of glo-
merular ﬁltration rate.
* p< 0.05 is signiﬁcant, p> 0.05 is not signiﬁcant.
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phritis as the commonest cause of ESRD (25.5%), while un-
known etiology was found in (17.3%).
In our study, 10 patients (25%) (seven patients in group I
and three patients in group II) were hypertensive. The propor-
tion of patients receiving ACE inhibitors was similar in both
groups. There was no statistically signiﬁcant difference in
systolic (SBP) and diastolic (DBP) at T0 and during follow
up between the two groups. However, antihypertensive
treatment had to be augmented in ﬁve patients receiving rHu-
Epo, with additional drugs prescribed in two, and increases of
previous dosage in three. This can be explained by the increase
in Hb and Hct levels which was slow, so no deleterious wors-
ening in hypertension occurred and no patients had to stop
rHuEpo.Komatsu and Ito (2007),11 stated that 20–50% of rHuEpo-
treated predialysis patients developed hypertension. Also,
Krapf and Hulter (2009),12 reported that rHuEpo-treated pa-
tients showed a trend to an increased risk for hypertension
by 26% compared with no rHuEpo/placebo, but the effect
was not statistically signiﬁcant.
In our study, the entire treated group started rHuEpo by
the SC route.
Szczech et al. (2008),13 showed that 30% of patients who re-
ceived rHuEpo intravenously developed an elevation in DBP
of 10 mmHg or more. In comparison, blood pressure is less
likely to rise after SC administration.
In our study, the incidence of microcytic hypochromic ane-
mia was 35% of the whole study group i.e. 14 patients (nine
patients in group I and ﬁve patients in group II), while the inci-
dence of normocytic normochromic anemia with high iron
stores (functional iron deﬁciency) was 40% of the whole study
group i.e. 16 patients (ﬁve patients in group I and 11 patients
in group II), with statistically signiﬁcant difference between the
two groups, with functional iron deﬁciency more in group II.
Johnson et al. (2007),14 stated that both absolute and func-
tional iron deﬁciency have been associated with sub-optimal
response to rHuEpo.
In agreement Sinnen (2008),15 stated that iron deﬁciency is
common in predialysis patients and replenishing iron stores in
anemic patients with CKD signiﬁcantly increases Hb levels
and should be considered as an integral part of the therapy
for treating anemia in the predialysis population.
In our study, there was highly statistically signiﬁcant differ-
ence between the initial and ﬁnal Hb levels and between the
initial and ﬁnal level of Hct in group I.
In agreement, Wanic-Kossowska et al. (2006),16 stated that
there was a signiﬁcant difference between the initial and ﬁnal
levels of the Hb and Hct in rHuEpo-treated patients.
In our study, there was highly statistically signiﬁcant differ-
ence between the two groups as regards Hb and Hct levels at
the end of the study. Also, there was statistically signiﬁcant dif-
ference between the two groups as regards transferrin satura-
tion (TSAT), being more in group II.
The rate of decline of GFR (DGFR) did not change in
group II. In contrast, the progression of CRF is already slower
before T0 in group I and decreased signiﬁcantly.
The slope of DGFR change in rHuEpo-treated group was
reduced by more than 50% in 10 patients whereas DGFR
did not signiﬁcantly change in the other 10 patients. Similarly,
the initial and ﬁnal values of GFR did not signiﬁcantly differ
between the two groups. When comparing the 10 patients
whose progression was slowed with the other 10 patients, the
only difference is the distribution of original renal disease be-
tween the two subgroups.
Several retrospective studies comparing renal function be-
fore and after rHuEpo treatment have found no evidence that
rHuEpo therapy accelerates the progression of renal failure
(Kato et al., 2010)17 and (Gouva et al., 2004).4
Dean et al. 2005,18 compared patients treated with rHuEpo
with patients not treated with rHuEpo. The slope of the in-
verse of serum creatinine was lower in the rHuEpo-treated
group.
Our study concluded that rHuEpo therapy is beneﬁcial for
the correction of renal anemia without worsening of blood
pressure or adverse effects on renal function.
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